[Senate Prints 114-27]
[From the U.S. Government Publishing Office]
114th Congress } { S. Prt.
COMMITTEE PRINT
2nd Session } { 114-27
______________________________________________________________________
HUMAN FETAL TISSUE RESEARCH:
CONTEXT AND CONTROVERSY
----------
MAJORITY STAFF REPORT
PREPARED FOR THE USE OF THE
COMMITTEE ON THE JUDICIARY
UNITED STATES SENATE
ONE HUNDRED FOURTEENTH CONGRESS
SECOND SESSION
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT]
DECEMBER 2016
Printed for the use of the Committee on the Judiciary
114th Congress } { S. Prt.
COMMITTEE PRINT
2nd Session } { 114-27
_______________________________________________________________________
HUMAN FETAL TISSUE RESEARCH:
CONTEXT AND CONTROVERSY
__________
MAJORITY STAFF REPORT
PREPARED FOR THE USE OF THE
COMMITTEE ON THE JUDICIARY
UNITED STATES SENATE
ONE HUNDRED FOURTEENTH CONGRESS
SECOND SESSION
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT]
DECEMBER 2016
Printed for the use of the Committee on the Judiciary
______
U.S. GOVERNMENT PUBLISHING OFFICE
22-920 PDF WASHINGTON : 2016
-----------------------------------------------------------------------
For sale by the Superintendent of Documents, U.S. Government Publishing
Office Internet: bookstore.gpo.gov Phone: toll free (866) 512-1800;
DC area (202) 512-1800 Fax: (202) 512-2104 Mail: Stop IDCC,
Washington, DC 20402-0001
COMMITTEE ON THE JUDICIARY
CHUCK GRASSLEY, Iowa, Chairman
ORRIN G. HATCH, Utah PATRICK J. LEAHY, Vermont, Ranking
JEFF SESSIONS, Alabama Member
LINDSEY GRAHAM, South Carolina DIANNE FEINSTEIN, California
JOHN CORNYN, Texas CHUCK SCHUMER, New York
MICHAEL S. LEE, Utah DICK DURBIN, Illinois
TED CRUZ, Texas SHELDON WHITEHOUSE, Rhode Island
JEFF FLAKE, Arizona AMY KLOBUCHAR, Minnesota
DAVID VITTER, Louisiana AL FRANKEN, Minnesota
DAVID PERDUE, Georgia CHRISTOPHER A. COONS, Delaware
THOM TILLIS, North Carolina RICHARD BLUMENTHAL, Connecticut
Kolan Davis, Chief Counsel and Staff Director
Kristine Lucius, Democratic Chief Counsel and Staff Director
C O N T E N T S
Page
Executive Summary................................................ 1
I. The Initial Public Debate About Fetal Tissue Research.............8
II. Congressional Response to the Fetal Research Debate..............10
III.The Return of the Fetal Tissue Debate in the Late 1980s..........12
A. The Human Fetal Tissue Transplantation Research Panel.........12
B. The George H.W. Bush Administration Rejects the Panel's
Recommendations.................................................14
C. Congressional Efforts To Overturn the Ban and Codify the Panel's
Recommendations.................................................14
D. President Clinton Lifts the Ban and Congress Codifies the
Panel's
Recommendations.................................................16
IV. The NIH Revitalization Act of 1993...............................17
A. The Terms of 42 U.S.C. Sec. 289g-1............................17
B. The Terms of 42 U.S.C. Sec. 289g-2............................18
C. GAO Verification Report.......................................19
D. Proposed Modification of 42 U.S.C.Sec. 289g-2 To Require
Reporting........................................................20
V. Media and Congressional Investigations Into Violations of 42
U.S.C.Sec. 289g-2 in the Year 2000..............................22
A. Call for Congressional Investigation..........................22
B. 20/20 Hidden-Camera Fetal Tissue Investigation................22
C. Hearing by the House Subcommittee on Health...................23
D. Another Proposed Modification of 42 U.S.C. Sec. 289g-2 To
Require
Reporting.......................................................26
E. 2000 GAO Report on Fetal Tissue Research......................26
F. Summary.......................................................27
VI. The Recent Controversy...........................................28
A. The Scope of the Committee's Investigation....................29
1. Laws Potentially Violated or in Need of Modification........29
2. Parties Involved............................................29
B. Advanced Bioscience Resources, Inc............................30
1. Contracts With Planned Parenthood Affiliates................31
2. ABR's Fetal Tissue Technicians..............................33
3. Contracts With ABR's Customers..............................34
4. Fetal Tissue Transaction Examples...........................35
5. ABR's Purported Cost Justification..........................38
C. StemExpress, LLC..............................................39
1. Contracts With Planned Parenthood Affiliates................40
2. StemExpress's Payments to Its Technicians...................41
3. Example of a StemExpress Fetal Tissue Transaction...........42
4. StemExpress's Purported Cost Justification..................42
D. Novogenix Laboratories, LLC...................................43
E. Planned Parenthood............................................44
1. PPFA's 2001 Fetal Tissue Policy.............................46
2. Developments in 2011........................................47
3. PPFA Stops Monitoring Affiliate Fetal Tissue Programs in
Accreditation Reviews............................................48
4. Policy Changes in May 2015..................................50
5. Planned Parenthood's Post Hoc Cost Calculations Created in
Response to the Committee's Inquiry..............................51
F. Continued Lack of Oversight and Enforcement...................53
VII. Conclusion.................................................. 54
Note Regarding Exhibits.......................................... 64
Combined Exhibits................................................ 65
Appendix I....................................................... 308
Appendix II...................................................... 403
Appendix III..................................................... 459
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT]
[all]